306 related articles for article (PubMed ID: 34292509)
21. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
[TBL] [Abstract][Full Text] [Related]
23. Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer.
Quatresooz P; Hermanns-Lê T; Piérard GE; Humbert P; Delvenne P; Piérard-Franchimont C
J Biomed Biotechnol; 2012; 2012():147413. PubMed ID: 22754278
[TBL] [Abstract][Full Text] [Related]
24. Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab.
Campbell K; Li K; Yang F; Branigan P; Elloso MM; Benson J; Orlovsky Y; Chen Y; Garcet S; Krueger JG
Immunohorizons; 2023 Apr; 7(4):273-285. PubMed ID: 37071038
[TBL] [Abstract][Full Text] [Related]
25. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
Gandhi M; Alwawi E; Gordon KB
Semin Cutan Med Surg; 2010 Mar; 29(1):48-52. PubMed ID: 20430307
[TBL] [Abstract][Full Text] [Related]
26. IL-23 inhibitors for moderate-to-severe psoriasis.
Ibler E; Gordon KB
Semin Cutan Med Surg; 2018 Sep; 37(3):158-162. PubMed ID: 30215632
[TBL] [Abstract][Full Text] [Related]
27. Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis.
Tan JY; Li S; Yang K; Ma B; Chen W; Zha C; Zhang J
J Dermatolog Treat; 2011 Dec; 22(6):323-36. PubMed ID: 20923370
[TBL] [Abstract][Full Text] [Related]
28. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.
Mahil SK; Ezejimofor MC; Exton LS; Manounah L; Burden AD; Coates LC; de Brito M; McGuire A; Murphy R; Owen CM; Parslew R; Woolf RT; Yiu ZZN; Uthman OA; Mohd Mustapa MF; Smith CH
Br J Dermatol; 2020 Oct; 183(4):638-649. PubMed ID: 32562551
[TBL] [Abstract][Full Text] [Related]
29. Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses.
Dommasch ED; Troxel AB; Gelfand JM
J Am Acad Dermatol; 2013 May; 68(5):863-5. PubMed ID: 23602173
[No Abstract] [Full Text] [Related]
30. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Li W; Ghamrawi R; Haidari W; Feldman SR
Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
[No Abstract] [Full Text] [Related]
31. Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?
Griffiths CE; Girolomoni G
J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():2-8. PubMed ID: 22758911
[TBL] [Abstract][Full Text] [Related]
32. Adverse Effects of Anti-Interleukin-23 Agents Employed in Patients with Psoriasis: A Systematic Review.
Naik PP
Dermatology; 2022; 238(5):886-896. PubMed ID: 35697004
[TBL] [Abstract][Full Text] [Related]
33. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.
Langley RG; Papp K; Gottlieb AB; Krueger GG; Gordon KB; Williams D; Valdes J; Setze C; Strober B
J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1252-61. PubMed ID: 23157612
[TBL] [Abstract][Full Text] [Related]
34. New and emerging therapies in psoriasis.
Leonardi CL; Gordon KB
Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S37-41. PubMed ID: 24979544
[TBL] [Abstract][Full Text] [Related]
35. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
Papp KA; Griffiths CE; Gordon K; Lebwohl M; Szapary PO; Wasfi Y; Chan D; Hsu MC; Ho V; Ghislain PD; Strober B; Reich K; ; ;
Br J Dermatol; 2013 Apr; 168(4):844-54. PubMed ID: 23301632
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
[TBL] [Abstract][Full Text] [Related]
37. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.
Tzellos T; Kyrgidis A; Zouboulis CC
J Eur Acad Dermatol Venereol; 2013 May; 27(5):622-7. PubMed ID: 22404103
[TBL] [Abstract][Full Text] [Related]
38. The role of IL 23 in the treatment of psoriasis.
Puig L
Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
[TBL] [Abstract][Full Text] [Related]
39. Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis.
Amin M; Darji K; No DJ; Wu JJ
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1627-1632. PubMed ID: 28667777
[TBL] [Abstract][Full Text] [Related]
40. Infliximab-induced psoriasis in an ulcerative colitis patient successfully treated with guselkumab.
Dai C; Huang YH
Rev Esp Enferm Dig; 2024 Mar; 116(3):176-177. PubMed ID: 37314119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
